+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Theranostics: Global Markets 2024-2029

  • PDF Icon

    Report

  • 118 Pages
  • August 2024
  • Region: Global
  • BCC Research
  • ID: 5178170

The global theranostics market was valued at USD 4.3 billion in 2024 and is forecast to grow at at CAGR of 24%, to reach USD 12.7 billion by 2029.

Report Scope

This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historical, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.

Report Includes

  • 45 data tables and 37 additional tables
  • An overview of the global markets for theranostics
  • Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
  • Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
  • Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
  • Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
  • Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
  • A discussion of ESG challenges and ESG practices in the industry
  • Analysis of the key companies’ market shares, proprietary technologies and strategic alliances
  • Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Overview
  • PESTLE Analysis
  • Political
  • Economic
  • Social
  • Technological
  • Legal
  • Environmental
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential of New Entrants
  • Competition in the Industry
  • Threat of Substitutes
  • R&D and Regulatory Approval
  • The Drug Development Process
  • Drug Discovery
  • Preclinical Development
  • Clinical Trials
  • The New Drug Application Review
  • NDA Data Review
  • Clinical Trials for Theranostics
  • Steps Followed for Radiotherapeutics in Clinical Trials
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Theranostics Replacing Conventional Treatment
  • Increased Application of Theranostics in Drug Discovery
  • Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
  • New Radiotheranostics Driving the Theranostics Market
  • Rise in Chronic Inflammatory Diseases
  • Cancer Epidemics in Developing Countries
  • Market Restraints
  • High Cost of Theranostics
  • Market Challenges
  • Nanotheranostics-Bio Interactions
  • Challenges of Radiotheranostics
  • Failure of Radiotherapeutics
  • Market Opportunities
  • Theranostics in Cardiovascular Diseases
Chapter 4 Emerging Technologies and Developments
  • Artificial Intelligence in Theranostics
  • Drug Delivery Using Innovative Material
  • Boron Neutron Capture Therapy (BNCT)
  • Luminogen Aggregation-Induced Emission (AIE)
  • Theranostics in Rheumatoid Arthritis (RA)
Chapter 5 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Analysis, by Product Type
  • Theranostics Equipment
  • Theranostics Agents
  • Diagnostics Theranostics Agents
  • Therapeutics Theranostics Agents
  • Market Analysis, by Application
  • Etiology of Cancer
  • Cancer Diagnosis
  • Cancer Therapeutics
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Thyroid Cancer
  • Neuroblastoma
  • Other Diseases
  • Geographic Breakdown
  • Market Analysis, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 6 Competitive Intelligence
  • Strategic Analysis
  • Clinical Trials Analysis
Chapter 7 Sustainability in Theranostics Market: An ESG Perspective
  • Introduction to ESG
  • Key ESG Issues in the Theranostics Market
  • Safety of Personnel
  • Disposal of Radioactive Waste
  • Nanopollution
  • Current Status of ESG in the Theranostics Market
  • ESG Performance Analysis
  • Concluding Remark
Chapter 8 Appendix
  • Methodology
  • Sources
  • Acronyms
  • Company Profiles
  • Bayer Ag
  • Curium Pharma
  • GE Healthcare
  • Lantheus
  • Novartis Ag
  • Siemens Healthineers Ag
  • Telix Pharmaceuticals Ltd.
  • Other Companies
List of Tables
Summary Table: Global Market for Theranostics, by Product Type, Through 2029
Table 1: Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2: Worldwide Regulatory Authorities, 2024
Table 3: Dosimetry Pre-therapy and Post-therapy
Table 4: Global Market for Theranostics, by Product Type, Through 2029
Table 5: Global Market for Theranostics Equipment, by Type, Through 2029
Table 6: Global Market for Theranostics Equipment, by Region, Through 2029
Table 7: Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8: Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9: Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10: Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11: Global Market for Theranostics Agents, by Type, Through 2029
Table 12: Global Market for Theranostics Agents, by Region, Through 2029
Table 13: Select Theranostics Pair
Table 14: Properties of Commonly Used Radionuclides in Theranostics
Table 15: Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16: Difference Between Alpha Particles and Beta Particles
Table 17: Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18: Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19: Advantages and Disadvantages of Various Cancer Treatments
Table 20: Global Market for Theranostics Applications, by Type, Through 2029
Table 21: Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22: Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23: Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24: Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25: Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26: Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27: North American Market for Theranostics, by Product Type, Through 2029
Table 28: North American Market for Theranostics Equipment, by Type, Through 2029
Table 29: North American Market for Theranostics Agents, by Type, Through 2029
Table 30: North American Market for Theranostics Applications, by Type, Through 2029
Table 31: North American Market for Theranostics, by Country, Through 2029
Table 32: Theranostics Centers Needed in the U.S.
Table 33: European Market for Theranostics, by Product Type, Through 2029
Table 34: European Market for Theranostics Equipment, by Type, Through 2029
Table 35: European Market for Theranostics Agents, by Type, Through 2029
Table 36: European Market for Theranostics Applications, by Type, Through 2029
Table 37: European Market for Theranostics, by Country, Through 2029
Table 38: Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39: Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40: Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41: Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42: Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43: Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44: Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45: Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46: Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47: Market Ranking, Theranostics Agents
Table 48: Strategic Analysis: Theranostics Market, 2021-2024
Table 49: Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50: The Three Pillars of ESG
Table 51: ESG Ranking of Leading Theranostics Players
Table 52: ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53: Report Information Sources
Table 54: Major Acronyms Used in the Global Theranostics Market
Table 55: Bayer AG: Company Snapshot
Table 56: Bayer AG: Financial Performance, FY 2022 and 2023
Table 57: Bayer AG: Product Portfolio
Table 58: Bayer AG: News/Key Developments, 2021-2023
Table 59: Curium Pharma: Company Snapshot
Table 60: Curium Pharma: Product Portfolio
Table 61: GE Healthcare: Company Snapshot
Table 62: GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63: GE Healthcare: Product Portfolio
Table 64: GE Healthcare: News/Key Developments, 2023-2024
Table 65: Lantheus: Company Snapshot
Table 66: Lantheus: Financial Performance, FY 2022 and 2023
Table 67: Lantheus: Product Portfolio
Table 68: Lantheus: News/Key Developments, 2023-2024
Table 69: Novartis AG: Company Snapshot
Table 70: Novartis AG: Financial Performance, FY 2022 and 2023
Table 71: Novartis AG: Product Portfolio
Table 72: Novartis AG: News/Key Developments, 2022
Table 73: Siemens Healthineers AG: Company Snapshot
Table 74: Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75: Siemens Healthineers AG: Product Portfolio
Table 76: Siemens Healthineers AG: News/Key Developments, 2022
Table 77: Telix Pharmaceutical Ltd.: Company Snapshot
Table 78: Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79: Telix Pharmaceutical Ltd.: Product Portfolio
Table 80: Telix Pharmaceutical Ltd.: News/Key Developments, 2022-2024
Table 81: Upcoming Startups in The Field of Theranostics

List of Figures
Summary Figure: Global Market for Theranostics, by Product Type, 2021-2029
Figure 1: Theranostics Workflow
Figure 2: Components of the Drug Approval Process
Figure 3: Preclinical and Clinical Trials Phases
Figure 4: Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5: Market Dynamics of Theranostics
Figure 6: Disadvantages of Chemotherapy Treatment
Figure 7: Drug Development Cost, 2002 and 2022
Figure 8: Global Market Shares of Theranostics, by Product Type, 2023
Figure 9: Global Market Shares of Theranostics, by Product Type, 2029
Figure 10: Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11: Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12: Schematic Representation of Radionuclide Therapy
Figure 13: Schematic Representation of Radionuclide Therapy
Figure 14: Etiology of Cancer
Figure 15: Cancer Diagnostics Methods
Figure 16: Types of Imaging
Figure 17: Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18: Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19: Share of Clinical Trials, by Recruiting Status, 2024
Figure 20: Share of Clinical Trials, by Type of Indication, 2024
Figure 21: Share of Clinical Trials, by Phase, 2024
Figure 22: Share of Clinical Trials, by Type of Funder, 2024
Figure 23: Share of Clinical Trials, by Gender, 2024
Figure 24: The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25: ESG Concerns in the Theranostics Market
Figure 26: Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27: Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28: GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29: GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30: Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31: Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32: Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35: Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023

Executive Summary

Theranostics is a combination of therapeutics and diagnostics. The main aim of theranostics is to provide diagnostics and therapeutics together to personalize treatment. The term was first coined by John Funkhouser in 1998. Theranostics is a prime example of personalized medicine. Radiotheranostics are applied via radionuclides, as they have properties for diagnosis and therapeutics. The primary application of theranostics is in the field of oncology.

The theranostics market is relatively new, being only about two decades old. A significant driver for theranostics is the inherent disadvantages of conventional cancer treatment. Chemotherapy has been the most widely used form of cancer treatment and is the first line of treatment for many cancers. However, chemotherapy has many disadvantages, such as adverse effects on healthy cells, loss of effectiveness on cancer cells and lack of a way to provide personalized treatment. With the help of theranostics, customized treatment can be provided to the patient, which helps overcome chemotherapy’s limitations and side effects.

One of the major factors driving the theranostics market is the rising number of cancer cases in both developed and developing countries. Cancer cases are on the rise in developed countries due to the population aging and earlier and more effective screening. In contrast, cancer cases are increasing in developing countries due to growth in the overall population and changing lifestyles. On the other hand, cancer mortality rates have been declining in many regions and countries. The declining mortality rates are due to advancements in cancer treatment and early detection. Nonetheless, the rising number of cancer patients will lead to a demand for new and better technology that effectively treats the disease and improves patients’ quality of life. This is possible through theranostics.

The market is faced with challenges and restraints that are holding the market back. One of the significant challenges of theranostics is the cost of treatment. Theranostics employs high-end equipment and reagents. Compared to other cancer treatments, the cost of theranostics procedures can be very high due to the involvement of many experts. It is one of the significant reasons for slow adoption, particularly in cost-sensitive markets.

Another challenge is the failure of some early radiotherapeutics. The current theranostics market is based on radionuclides. Commercial failure of these drugs has significantly hindered the market’s growth. Investors may be hesitant due to a lack of return on investments.

The major opportunity in the market is for treating cancer, particularly prostate cancer and neuroendocrine tumors. Theranostics can also be applied to other cancers. Radionuclides are conjugated with antibodies, proteins and other biomarkers to achieve targeted radionuclide therapy."

Companies Mentioned

  • Bayer AG
  • Curium Pharma
  • GE Healthcare
  • Lantheus
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Ltd.

Table Information